Anticancer carrier-linked prodrugs in clinical trials

Bibliography

• JAIN RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev. (1987) 6(4):559-593.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules, particles, and cells in solid tumors. Ann. Rev. Biomed. Eng. (1999) 1:241-263.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, GHOSH RN, MAXFIELD FR: Endocytosis. Physiol. Rev. (1997) 77(3):759-803.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, ROTIN D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. (1989) 49(16):4373-4384.
   PubMed Web of Science ®Google Scholar
• RIHOVA B, KUBACKOVA K: Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr. Pharm. Biotechnol. (2003) 4(5):311-322.
   PubMedGoogle Scholar
• HAAG R, KRATZ F: Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. (2006) 45(8):1198-1215.
   PubMed Web of Science ®Google Scholar
• WU AM, SENTER PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. (2005) 23(9):1137-1146.
   PubMed Web of Science ®Google Scholar
• VICENT MJ, DUNCAN R: Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. (2006) 24(1):39-47.
   PubMed Web of Science ®Google Scholar
• KRATZ F, WARNECKE A, SCHMID B, CHUNG DE, GITZEL M: Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. (2006) 13(5):477-523.
   PubMed Web of Science ®Google Scholar
• ROSS HJ, HART LL, SWANSON PM et al.: A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer (2006) 54(1):69-77.
   PubMed Web of Science ®Google Scholar
• SMITH SV: Technology evaluation: huN901-DM1, ImmunoGen. Curr. Opin. Mol. Ther (2005) 7(4):394-401.
   PubMed Web of Science ®Google Scholar
• SMITH S: Technology evaluation: C242-DM1, ImmunoGen Inc. Curr. Opin. Mol. Ther. (2001) 3(2):198-203.
   PubMed Web of Science ®Google Scholar
• TASSONE P, GOLDMACHER VS, NERI P et al.: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 104(12):3688-3696.
   PubMed Web of Science ®Google Scholar
• HENRY MD, WEN S, SILVA MD et al.: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. (2004) 64(21):7995-8001.
   PubMed Web of Science ®Google Scholar
• SMITH SV: Technology evaluation: cantuzumab mertansine, ImmunoGen. Curr. Opin. Mol. Ther. (2004) 6(6):666-674.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, OCHOA L, HAMMOND LA et al.: Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. (2003) 21(2):211-222.
   PubMed Web of Science ®Google Scholar
• HELFT PR, SCHILSKY RL, HOKE FJ et al.: A Phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin. Cancer Res. (2004) 10(13):4363-4368.
   PubMed Web of Science ®Google Scholar
• ABUTALIB SA, TALLMAN MS: Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr. Pharm. Biotechnol. (2006) 7(5):343-369.
   PubMed Web of Science ®Google Scholar
• BROSS PF, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. (2001) 7(6):1490-1496.
   PubMed Web of Science ®Google Scholar
• JARACZ S, CHEN J, KUZNETSOVA LV, OJIMA I: Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. (2005) 13(17):5043-5054.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93(11):3678-3684.
   PubMed Web of Science ®Google Scholar
• TRAIL PA, WILLNER D, LASCH SJ et al.: Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res. (1992) 52(20):5693-5700.
   PubMed Web of Science ®Google Scholar
• TRAIL PA, WILLNER D, LASCH SJ et al.: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 261(5118):212-215.
   PubMed Web of Science ®Google Scholar
• TRAIL PA, WILLNER D, KNIPE J et al.: Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res. (1997) 57(1):100-105.
   PubMed Web of Science ®Google Scholar
• TRAIL PA, WILLNER D, BIANCHI AB et al.: Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin. Cancer Res. (1999) 5(11):3632-3638.
   PubMed Web of Science ®Google Scholar
• SALEH MN, SUGARMAN S, MURRAY J et al.: Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. (2000) 18(11):2282-2292.
   PubMed Web of Science ®Google Scholar
• AJANI JA, KELSEN DP, HALLER D, HARGRAVES K, HEALEY D: A multi-institutional Phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. (2000) 6(2):78-81.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, SUGARMAN S, GELMON KA et al.: Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. (1999) 17(2):478-484.
   PubMed Web of Science ®Google Scholar
• KEHRER DFS, SOEPENBERG O, LOOS WJ, VERWEIJ J, SPARREBOOM A: Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs (2001) 12:89-105.
   PubMed Web of Science ®Google Scholar
• BURKE TG, MUNSHI CB, MI Z, JIANG Y: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci. (1995) 84(4):518-519.
   PubMed Web of Science ®Google Scholar
• BURKE TG, BOM D: Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann. NY Acad. Sci. (2000) 922:36-45.
   PubMed Web of Science ®Google Scholar
• MI Z, BURKE TG: Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopy study. Biochemistry (1994) 33:12540-12545.
   PubMed Web of Science ®Google Scholar
• ZHAO H, LEE C, SAI P et al.: 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J. Org. Chem. (2000) 65:4601-4606.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, CREAVEN PJ, HANSEN HH: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. (1972) 56:515-521.
   PubMedGoogle Scholar
• POSEY JA III, SAIF MW, CARLISLE R et al.: Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. (2005) 11(21):7866-7871.
   PubMed Web of Science ®Google Scholar
• SARAPA N, BRITTO MR, SPEED W et al.: Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. (2003) 52(5):424-430.
   PubMed Web of Science ®Google Scholar
• ZAMAI M, VANDEVEN M, FARAO M et al.: Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol. Cancer Ther. (2003) 2(1):29-40.
   PubMed Web of Science ®Google Scholar
• NOGUCHI Y, WU J, DUNCAN R et al.: Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J. Cancer Res. (1998) 89:307-314.
   PubMedGoogle Scholar
• WACHTERS FM, GROEN HJ, MARING JG et al.: A Phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer (2004) 90(12):2261-2267.
   PubMed Web of Science ®Google Scholar
• SCOTT LC, EVANS T, YAO JC et al.: Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: preliminary results of a single-agent Phase II study. J. Clin. Oncol. (Meeting Abstracts) (2004) 22(14S):4030.
   Google Scholar
• VASEY PA, KAYE SB, MORRISON R et al.: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. (1999) 5(1):83-94.
   PubMed Web of Science ®Google Scholar
• BILIM V: Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr. Opin. Mol. Ther. (2003) 5(3):326-330.
   PubMed Web of Science ®Google Scholar
• LOADMAN PM, BIBBY MC, DOUBLE JA, AL-SHAKHAA WM, DUNCAN R: Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin. Cancer Res. (1999) 5(11):3682-3688.
   PubMed Web of Science ®Google Scholar
• SEYMOUR LW, FERRY DR, ANDERSON D et al.: Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. (2002) 20(6):1668-1676.
   PubMed Web of Science ®Google Scholar
• KRATZ F, EHLING G, KAUFFMANN HM, UNGER C: Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum. Exp. Toxicol. (2007) 26(1):19-35.
   PubMed Web of Science ®Google Scholar
• KRATZ F, WARNECKE A, SCHEUERMANN K et al.: Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. (2002) 45:5523-5533.
   PubMed Web of Science ®Google Scholar
• LEBRECHT D, GEIST A, KETELSEN UP et al.: The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer (2007) 120(4):927-934.
   PubMed Web of Science ®Google Scholar
• KRATZ F, EHLING G, KAUFFMANN H, UNGER C: Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum. Exp. Toxicol. (2007) 26(1):19-35.
   PubMed Web of Science ®Google Scholar
• LEBRECHT D, GEIST A, KETELSEN U et al.: The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer (2007) 120(4):927-934.
   PubMed Web of Science ®Google Scholar
• UNGER C, HÄRING B, MEDINGER M et al.: Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Clin. Cancer Res. (2007) (Submitted).
   PubMedGoogle Scholar
• KRATZ F: DOXO-EMCH (INNO-206), the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs (2007) 16(6):855-866.
   PubMed Web of Science ®Google Scholar
• STEHLE G, SINN H, WUNDER A et al.: The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs (1997) 8(7):677-685.
   PubMed Web of Science ®Google Scholar
• STEHLE G, WUNDER A, SINN H et al.: Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs (1997) 8(9):835-844.
   PubMed Web of Science ®Google Scholar
• WOSIKOWSKI K, BIEDERMANN E, RATTEL B et al.: In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin. Cancer Res. (2003) 9(5):1917-1926.
   PubMed Web of Science ®Google Scholar
• HARTUNG G, STEHLE G, SINN H et al.: Phase I trial of a methotrexate-albumin in a weekly intravenous bolus rgimen in cancer patients. Clin. Cancer Res. (1999) 5(4):753-759.
   PubMed Web of Science ®Google Scholar
• VIS AN, VAN DER GAAST A, VAN RHIJN BW et al.: A Phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother. Pharmacol. (2002) 49(4):342-345.
   PubMed Web of Science ®Google Scholar
• BOLLING C, GRAEFE T, LUBBING C et al.: Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs (2006) 24(6):521-527.
   PubMed Web of Science ®Google Scholar
• PESENTI E, FRANZETTI C, CIOMEI M: Synthesis and biological activity of water soluble polymer-bound taxol derivatives. Proc. Am. Assoc. Cancer Res. (1995) 36:307.
   Google Scholar
• MEERUM TERWOGT JM, TEN BOKKEL HUININK WW, SCHELLENS JH et al.: Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs (2001) 12(4):315-323.
   PubMed Web of Science ®Google Scholar
• GREENWALD RB, GILBERT CW, PENDRI A et al.: Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs – design and in vivo effectiveness. J. Med. Chem. (1996) 39:424-431.
   PubMed Web of Science ®Google Scholar
• PENDRI A, CONOVER CD, GREENWALD RB: Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Design (1998) 13(5):387-395.
   PubMedGoogle Scholar
• BEERAM M, ROWINSKY EK, HAMMOND LA et al.: A Phase I and pharmacokinetic (PK) study of PEG-paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:405 (Abstract).
   Google Scholar
• SINGER JW, SHAFFER S, BAKER B et al.: Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs (2005) 16(3):243-254.
   PubMed Web of Science ®Google Scholar
• SHAFFER SA, BAKER-LEE C, KENNEDY J et al.: In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother. Pharmacol. (2007) 59(4):537-548.
   PubMed Web of Science ®Google Scholar
• BODDY AV, PLUMMER ER, TODD R et al.: A Phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. (2005) 11(21):7834-7840.
   PubMed Web of Science ®Google Scholar
• VERONESE ML, FLAHERTY K, KRAMER A et al.: Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2005) 55(5):497-501.
   PubMed Web of Science ®Google Scholar
• SABBATINI P, AGHAJANIAN C, DIZON D et al.: Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. (2004) 22(22):4523-4531.
   PubMed Web of Science ®Google Scholar
• DIPETRILLO T, MILAS L, EVANS D et al.: Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a Phase I study. Am. J. Clin. Oncol. (2006) 29(4):376-379.
   PubMed Web of Science ®Google Scholar
• ALBAIN KS, BELANI CP, BONOMI P et al.: PIONEER: a Phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin. Lung Cancer (2006) 7(6):417-419.
   PubMed Web of Science ®Google Scholar
• SINGER JW: Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Control. Release (2005) 109(1-3):120-126.
   PubMed Web of Science ®Google Scholar
• MAN M, RUGO H: Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs (2005) 8(9):739-754.
   PubMed Web of Science ®Google Scholar
• LANGER CJ: CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer (2004) 6(Suppl. 2):S85-S88.
   PubMedGoogle Scholar
• LANGER CJ: CT-2103: emerging utility and therapy for solid tumours. Expert Opin. Investig. Drugs (2004) 13(11):1501-1508.
   PubMed Web of Science ®Google Scholar
• MARKMAN M: Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103. J. Exp. Ther. Oncol. (2004) 4(2):131-136.
   PubMedGoogle Scholar
• SOOD P, THURMOND KB II, JACOB JE et al.: Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjugate Chem. (2006) 17(5):1270-1279.
   PubMed Web of Science ®Google Scholar
• RICE JR, GERBERICH JL, NOWOTNIK DP, HOWELL SB: Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res. (2006) 12(7 Part 1):2248-2254.
   PubMed Web of Science ®Google Scholar
• RADEMAKER-LAKHAI JM, TERRET C, HOWELL SB et al.: A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. (2004) 10(10):3386-3395.
   PubMed Web of Science ®Google Scholar
• RIHOVA B, ETRYCH T, PECHAR M et al.: Doxorubicin bound to HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J. Control. Release (2001) 74:225-232.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, RIZZO J, OCHOA L et al.: A Phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. (2003) 21(1):148-157.
   PubMed Web of Science ®Google Scholar
• SCHOEMAKER NE, VAN KESTEREN C, ROSING H et al.: A Phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer (2002) 87(6):608-614.
   PubMed Web of Science ®Google Scholar
• BISSETT D, CASSIDY J, DE BONO JS et al.: Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer (2004) 91(1):50-55.
   PubMed Web of Science ®Google Scholar
• MCNAMARA MV, DOROSHOW JH, DUPONT J et al.: Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol. (Meeting Abstracts) (2004) 22(Suppl. 14):2073.
   Google Scholar
• DAUD A, GARRETT C, SIMON GR et al.: Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):2015.
   Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, SENZER N et al.: Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. (2005) 23(8):671-676.
   PubMed Web of Science ®Google Scholar